PT - JOURNAL ARTICLE AU - Caceres, Juan AU - Zhang, Yibing AU - Boe, Lawrence AU - Zhou, Yunshu AU - Besirli, Cagri AU - Paulus, Yannis M AU - Rosenthal, Julie M. TI - Diabetic retinopathy screening using a portable retinal camera in Vanuatu AID - 10.1101/2022.05.25.22275597 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.25.22275597 4099 - http://medrxiv.org/content/early/2022/05/30/2022.05.25.22275597.short 4100 - http://medrxiv.org/content/early/2022/05/30/2022.05.25.22275597.full AB - Background and Objective Proof-of-concept study to test the feasibility of using an all-in-one portable retinal camera for the screening of diabetic retinopathy in the Pacific island of Vanuatu.Study Design/Materials and Methods From February 10, 2020, through February 28, 2020, 49 patients with diabetes mellitus from three islands in Vanuatu were recruited to participate in the study. Demographics, basic health data and retinal photography were obtained. A non-mydriatic, handheld camera was used (Volk Pictor Plus).Results Eleven participants (24%) had referral-warranted diabetic retinopathy. There was moderately high inter-rater reliability for our dependent variables: referral status (κ = 0.62, 95% CI 0.42-0.83), retinopathy severity (κ = 0.76, 95% CI 0.55-0.96), and clinically significant macular edema (κ = 0.50, 95% CI 0.25-0.74)Conclusions Our study confirms that portable handheld cameras can be used to obtain retinal images of sufficient quality for diabetic retinopathy screening even in resource limited environments like Vanuatu. Among this cohort, a relatively high (24%) prevalence of referral-warranted diabetic retinopathy was found in Vanuatu.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author's travel expenses were funded by Global Reach as part of the University of Michigan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at the University of Michigan (HUM00171292, Diabetic Retinopathy in Vanuatu) and the Ethics Committee at the Vanuatu Ministry of Health. Informed consent was obtained from all individuals participating in the described study. Visual acuity had a retrospective approval by the Vanuatu Ministry of Health given minimal risk.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data cannot be shared publicly because of HIPAA. Data is available from the University of Michigan Institutional Data Access/ Ethics Committee. Contact Dr. Paulus or Dr. Rosenthal for researchers who meet the criteria to access confidential de-identified data.The data cannot be shared publicly because of HIPAA. Data is available from the University of Michigan Institutional Data Access/ Ethics Committee. Contact Dr. Paulus or Dr. Rosenthal for researchers who meet the criteria to access confidential de-identified data.